Nurix Therapeutics (NRIX) Stock: Slides as Losses Widen Despite Pipeline Progress
TLDR NRIX dips 1.65% as losses widen despite pipeline progress Revenue drops sharply as Sanofi collaboration contributions decline R&D spending rises on accelerated clinical trial...












